PQ912 delivers positive pharmacodynamic and efficacy results in a Phase-2a study in early stage AD patients

Successful settlement of longpending tax issue

PQ912 demonstrates efficacy in a preclinical Huntington`s disease model

HALLE (SAALE), Germany, 31 August 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announced its financial results for the first six months ending 30 June 2017, prepared in accordance with German GAAP (“HGB”) and, on a voluntary basis, in accordance with IFRS as endorsed by the European Union. The reports are available on the company website (http://www.probiodrug.de/investors/reports-and-presentations/).

KEY HIGHLIGHTS
•PQ912 delivers positive pharmacodynamic and efficacy results in a Phase-2a study, the SAPHIR study, in early stage AD patients
•Successful settlement of the potential tax liability resulting from 2004
•PQ912 demonstrates efficacy in preclinical Huntington`s disease model
•Publication of PQ912 pharmacology paper in a peer reviewed journal: ‘Glutaminyl Cyclase Inhibitor PQ912 improves cognition in mouse models of Alzheimer’s disease – studies on relation to effective target occupancy’
•New positive results with PQ912 and PBD-C06 alone and in combination in AD animal models presented
•Annual Shareholders’ Meeting held on 13 June 2017
•Expenditures and corresponding cash position in line with management expectations
•As of 30 June 2017, Probiodrug held EUR 14.4 million in cash and cash equivalents


POST PERIOD HIGHLIGHTS

There were no significant events subsequent to the reporting period.

tijd 09.46
Probiodrug EUR 14,205 -29ct vol. 1.760